4Vakiani E, Solit D B. KRAS and BRAF: drug targets and pre- dictive biomarkers[J]. J Pathol, 2011,223(2):219-229.
5Yu S H, Wang T H, Au L C. Specific repression of mutant K-RAS by 10-23 DNAzyme: Sensitizing cancer cell to anti- cancer therapies[J]. Biochem Biophys Res Commun, 2009,378 (2):230-234.
6Przybojewska B, Jagiello A, Jalmuzna P. H-RAS, K-RAS, and N-RAS gene activation in human bladder cancers[J]. Can- cer Genet Cytogenet, 2000,121(1):73-77.
7Knobbe C B, Reifenberger J, Reifenberger G. Mutation analy- sis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas[J]. Acta Neuropathol, 2004,108(6): 467-470.
8Hou W, Liu J, Chen P, et al. Mutation analysis of key genes in RAS/RAF and PI3K/PTEN pathways in Chinese patients with hepatocellular carcinoma[J], Oneol Lett, 2014,8(3):1249- 1254.
9McCubrey J A, Steelman L S, Chappell W H, et al. Ras/Raf/ MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to over- come resistance[J]. Oncotarget, 2012,3(10):1068-1111.
10Therkildsen C, Bergmann T K, Henrichsen-Schnack T, et al. The predictive value of KRAS, NRAS, BRAF , PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal can- cer: a systematic review and meta-analysis[J]. Acta Oncol, 2014,53(7):852-864.
